Phase 4 N=4,730 A Toolbox Approach to Obesity Treatment in Primary Care
Obesity
Primary: Percentage of Participants Who Achieved >5% Weight Loss at 12 Months — 34.5; 15.7 percentage of participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD
COPD
Primary: Airway Blood Flow Reactivity (Delta Qaw) — 29.1; 13.7; 8.9; 15.6 % of change
Phase 2 N=12 Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
Cannabis Dependence
Primary: Change in Marijuana Use — -1.7 days
N/A N=25 Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
Phase 2 N=39 Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Response — 0; 10; 1; 0 Participants
Phase 2 N=44 Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Head and Neck Cancer
Primary: Progression-free Survival at 2 Years — 75.9 percentage of participants
Phase 3 N=299 Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib
Whole Cell Pertussis · Haemophilus Influenzae Type b · Tetanus
Primary: Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) Antigens — 93; 84; 89 Participants
Phase 3 N=615 A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
Kidney Neoplasms
Primary: Disease-free Survival (DFS)- Assessed by Blinded Independent Central Review — 6.8; 5.6 Number of years — p=0.030
Phase 2 N=10 Study of SCY-635, Pegasys and Copegus in Hepatitis C
Hepatitis C Infection
Primary: Undetectable HCV RNA — 0; 1 participants
Phase 3 N=503 Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Hemorrhage
Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT — 100.0; 100.0; 100.0; 100.0 percentage
Phase 2 N=176 A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
Lymphoma · Leukemia · Multiple Myeloma
Primary: Number of Participants DLT in Arm 1 in Dose Escalation Phase — 0; 0; 2; 1 Participants
Phase 2 N=43 Effects of Varenicline on Smoking Reminders
Nicotine Dependence
Primary: Cigarettes Per Day — 15.7; 14.3; 9.8; 5.3 cigarettes per day — p=0.0004
Phase 4 N=42 Clopidogrel Versus Ticagrelor in Type-2 Diabetes
Coronary Artery Disease · Diabetes Mellitus
Primary: Flow-mediated Dilation of the Brachial Artery — 16.6; 11.6 FMD (%)
Phase 2 N=83 Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Malignant Neoplasm
Primary: Grade 3-4 Acute GVHD — 0.21 probability
Phase 4 N=10 Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers
Smoking
Primary: Measurement of Maximum Serum Concentration (Cmax) — 27.47; 21.32; 28.04; 22.96 ng/mL